CD46-Specific CAR-T Cells for Cancer Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies lack effective targeting mechanisms for cancer cells overexpressing CD46, which are common in various cancers and associated with poor prognosis, necessitating a more specific and potent therapeutic approach.
Innovation Solution
Engineered effector cells, such as CAR-T cells and CAR-NK cells, are developed to specifically bind to CD46 using antigen binding domains like scFv, which are displayed on their surface, combined with costimulatory signaling domains to enhance their potency and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional cancer therapies are used, then treatment is provided, but targeting specificity for CD46-overexpressing cancer cells is insufficient
Solution Approach 1:
The therapeutic system is segmented into multiple functional components: CD46-specific antigen binding domains (scFv, Fab, or other antibody fragments) for targeting, costimulatory signaling domains (CD28, 4-1BB, OX40, ICOS, or CD137) for activation, and effector cells (T cells or NK cells) for execution. This segmentation allows each component to be optimized independently for its specific function, achieving both high targeting specificity and treatment effectiveness.
Solution Approach 2:
The engineered effector cells are designed with multi-functionality by combining multiple domains within a single cell: the antigen binding domain provides targeting, the costimulatory signaling domains provide activation and proliferation signals, and the effector cell provides cytotoxic activity. This universal design enables a single therapeutic product to address multiple requirements simultaneously.
2Reliability
If engineered effector cells with multiple domains are created, then targeting and potency are enhanced, but device complexity increases
Solution Approach 1:
Multiple functional elements are merged into a single integrated effector cell through transduction with viral vectors (such as lentivirus or retrovirus). The antigen binding domain, costimulatory signaling domains, and effector cell components are combined into one unified therapeutic product, simplifying administration while maintaining high reliability through the synergistic interaction of integrated components.
Solution Approach 2:
The engineering process involves systematic parameter changes in the antigen binding domain (selecting different scFv, Fab, or other antibody fragments with varying affinities and specificities) and costimulatory signaling domains (combining different combinations of CD28, 4-1BB, OX40, ICOS, or CD137) to optimize the balance between targeting specificity and cellular potency for different cancer types.
3Reliability
If autologous effector cells are used, then patient compatibility is improved, but manufacturing complexity and time increase
Solution Approach 1:
Allogeneic effector cells are prepared in advance and stored in a frozen state before use. This preliminary preparation eliminates the need for time-consuming autologous cell collection, processing, and expansion at the time of treatment. The cells are pre-engineered with the necessary antigen binding domains and costimulatory signaling domains, then thawed and administered to the patient, significantly reducing manufacturing time while maintaining patient compatibility through careful selection and matching.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These engineered cells effectively target and deplete CD46-overexpressing cancer cells, offering a promising therapeutic strategy for cancers like breast, lung, and prostate cancer, potentially improving treatment outcomes by enhancing cellular specificity and potency.
Implementation Method 1
an engineered effector cell that specifically binds CD46, comprising an engineered antigen binding domain that binds to an epitope of CD46
Implementation Method 2
These engineered cells effectively target and deplete CD46-overexpressing cancer cells
Data Source
AI summary
Engineered effector cells, such as chimeric antigen receptors (CARs), are used for enhanced immunogenic response to specific antigen, such as CD46. Disclosed herein are compositions and methods of treatment a cancer overexpressing CD46, which comprises a pharmaceutical composition comprising an engineered effector cell.